Related Experiment Videos
Protection against vaginal SIV transmission with microencapsulated vaccine
P A Marx1, R W Compans, A Gettie
1New Mexico Regional Primate Research Laboratory, New Mexico State University, Holloman Air Force Base 88330.
Abstract:
Although protection in animal models against intravenous challenges with simian immunodeficiency virus (SIV) has been reported, no previous vaccines have protected against a heterosexual route of infection. In this study, five of six macaques were protected against vaginal challenge when immunized with formalin-treated SIV in biodegradable microspheres by the intramuscular plus oral or plus intratracheal route. Oral immunization alone did not protect. After a second vaginal challenge, three of four intramuscularly primed and mucosally boosted macaques remained protected. The data suggest that protection against human immunodeficiency virus vaginal transmission could be provided by microsphere-based booster vaccines when used to immunize women who are systemically primed.
Insights
New SIV vaccine strategies show promise for preventing heterosexual transmission. Microsphere-based vaccines protected macaques against vaginal simian immunodeficiency virus (SIV) challenges, suggesting potential for human immunodeficiency virus (HIV) prevention.
Area of Science:
- Immunology
- Vaccinology
- Virology
Background:
- Previous simian immunodeficiency virus (SIV) vaccines demonstrated protection against intravenous challenges.
- No prior vaccine strategies have successfully prevented heterosexual SIV infection in animal models.
Purpose of the Study:
- To evaluate the efficacy of a novel SIV vaccine formulation delivered via biodegradable microspheres against vaginal SIV challenge.
- To determine if mucosal and systemic immunization routes enhance vaccine-induced protection.
Main Methods:
- Macaca mulatta were immunized with formalin-inactivated SIV encapsulated in biodegradable microspheres.
- Immunization routes included intramuscular (IM) plus oral (PO) or intramuscular plus intratracheal (IT).
- Animals were subsequently challenged vaginally with SIV, with some receiving a second challenge after mucosal boosting.
Main Results:
- Five of six macaques receiving IM plus PO or IM plus IT immunization were protected against initial vaginal SIV challenge.
- Oral immunization alone did not confer protection.
- Following a second vaginal challenge, three of four macaques that received IM priming and mucosal boosting remained protected.
Conclusions:
- Biodegradable microsphere-based SIV vaccines delivered via combined systemic and mucosal routes can protect against vaginal SIV challenge.
- This approach holds potential for developing vaccines to prevent heterosexual human immunodeficiency virus (HIV) transmission.
- Further research is warranted to explore the application of these findings to human HIV vaccine development.